Repurposing of rilpivirine for preventing platelet β3 integrin-dependent thrombosis by targeting c-Src active autophosphorylation

HIV-infected individuals are known to be at higher risk for thrombotic cardiovascular disease (CVD), which may also be differentially affected by components of anti-HIV drugs. To identify the effects of a series of FDA-approved anti-HIV drugs on platelet aggregation in humans, focusing on the novel pharmacological effects of rilpivirine (RPV), a reverse transcriptase inhibitor, on platelet function both in vitro and in vivo and the mechanisms involved.

Source: Thrombosis Research - July 1, 2023 Category: Hematology Authors: Kui Liu, Zhen Hao, Hao Zheng, Haojie Wang, Luying Zhang, Minghui Yan, Reyisha Tuerhong, Yuling Zhou, Yan Wang, Tao Pang, Lei Shi Tags: Full Length Article Source Type: research